Legal Representation
Attorney
Malaika D. Tyson
USPTO Deadlines
Next Deadline
27 days remaining
Non-Final Action E-Mailed
Due Date
February 28, 2026
Extension Available
Until May 28, 2026
Application History
18 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 10, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Dec 10, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Dec 10, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Nov 29, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Nov 29, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Nov 29, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Sep 10, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Sep 10, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Sep 10, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| May 28, 2025 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| May 28, 2025 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Mar 10, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 10, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Mar 10, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 3, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Feb 26, 2025 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Feb 26, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Aug 26, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical products for the prevention and treatment of cancer and autoimmune disorders; therapeutic pharmaceuticals for the treatment of cancer and autoimmune disorders; anti-cancer preparations being anti-cancer medicines comprised of small molecules and biologics; pharmaceuticals and therapeutic pharmaceuticals for the treatment of cancer and autoimmune disorders and for use in the fields of oncology and immunology
First Use Anywhere:
20240600
First Use in Commerce:
20240600
Class 042
Pharmaceutical research and development; scientific research and development; medical research and development in the fields of oncology, autoimmunity, and immunology; medical research and development services in the fields of drug discovery and oncology, autoimmunity, and immunology
First Use Anywhere:
20240600
First Use in Commerce:
20240600
Additional Information
Design Mark
The mark consists of the literal elements CULLINAN THERAPEUTICS with a stylized wing appearing over the "I" in CULLINAN.
Color Claim
Color is not claimed as a feature of the mark.
Other
CULLINAN has become distinctive of the goods/services through the applicant's substantially exclusive and continuous use of the mark in commerce that the U.S. Congress may lawfully regulate for at least the five years immediately before the date of this statement. CULLINAN has become distinctive of the goods/services as evidenced by the ownership on the Principal Register for the same mark for sufficiently similar goods/services of active U.S. Registration No(s). 7797946
Classification
International Classes
005
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"